Translational Development Acquisition Corp. (TDAC)

Translational Development Acquisition Corp. is a special purpose acquisition company, also known as a blank-check company, based in New York. It was incorporated in 2022 and completed its initial public offering on the Nasdaq in 2024.

The company was formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It does not have significant operations of its own, and the funds raised in its offering are held in trust until a business combination is completed or the company liquidates.

As its name suggests, the company's sponsor team has a background in translational medicine and life sciences, and it has indicated an interest in healthcare and biotechnology businesses. Its ordinary shares trade on the Nasdaq under the ticker TDAC.